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Abstract
Respiratory virus infections precipitate asthma and chronic obstructive pul-
monary disease (COPD) exacerbations, with most exacerbations due to rhi-
novirus infection. Both asthma and COPD exacerbations are not well controlled
by steroid therapies, and there is a much research interest in finding improved
therapies or combinations of therapies for controlling exacerbations. CHF6001 is
a new, inhaled highly potent and selective phosphodiesterase type 4 (PDE4) inhi-
bitor. Using in vitro human bronchial epithelial cells (BEAS-2B), we investigated
the potential anti-inflammatory effects of CHF6001 on rhinovirus (RV1B)-
induced cytokines. Cytokine mRNA was measured by real-time PCR, while
protein release was measured by ELISA. CHF6001 was used in a 7-point dose–
response curve (1000–0.001 nmol/L) as a 1.5-h pretreatment prior to infection in
comparison with roflumilast. Both roflumilast and CHF6001 reduced RV1B-
induced IL-8, IL-29, IP-10, and RANTES mRNA and protein in a concentration-
dependent manner. Generally, CHF6001 was 13- to 16-fold more potent (sub-
nanomolar EC50 values) than roflumilast at reducing IL-8, IL-29, IP-10, and
RANTES mRNA and protein release, but had similar efficacies. In combination
with the steroid fluticasone propionate (1 nmol/L), CHF6001 had additive
effects, significantly reducing RV-induced cytokines when compared with steroid
or CHF6001 alone. Combined low-dose steroid and low-dose CHF6001 had a
similar efficacy as high-dose steroid or CHF6001 alone, indicating the combina-
tion had steroid and PDE4 inhibitor sparing effects. Overall results indicate that
PDE4 inhibitors have anti-inflammatory activity against virus-induced inflamma-
tory mediators and that CHF6001 is more potent than roflumilast.
Abbreviations
COPD, chronic obstructive pulmonary disease; FP, fluticasone propionate; GR, glu-
cocorticoid receptor; IFN, interferon; MOI, multiplicity of infection; PDE, phos-
phodiesterase; PRRs, pattern recognition receptors; RLHs, RIG-like helicases; RSV,
respiratory syncytial virus; RV, human rhinovirus; TLR, toll-like receptor.
Introduction
The majority of exacerbations of asthma and chronic
obstructive pulmonary disease (COPD) are triggered by
acute respiratory virus infections (Edwards et al. 2012a;
Johnston et al. 2005, 1995; Papadopoulos et al. 2010). Res-
piratory syncytial viruses (RSV), influenza viruses, metap-
neumoviruses, bocaviruses, and parainfluenza viruses
can all precipitate asthma and COPD exacerbations, but
the most common virus associated with exacerbations of
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either disease is human rhinoviruses (RVs). RVs account
for up to 80% of asthma exacerbations in children (Bizzin-
tino et al. 2010; Johnston et al. 1995) and approximately
60% of asthma exacerbations in adults (Nicholson et al.
1993) and up to 50% of total COPD exacerbations
(Seemungal et al. 2001).
Asthma and COPD exacerbations represent a major
unmet medical need, with current treatments for stable
asthma and COPD (inhaled corticosteroids and b2 ago-
nists) only showing small improvements in both exacer-
bation rate (Bisgaard et al. 2006; Calverley et al. 2003,
2007a; Dal Negro et al. 2003; Kuna et al. 2007; Nannini
et al. 2003; O’Byrne et al. 2005; Vogelmeier et al. 2005)
and severity (Calverley et al. 2003; Dal Negro et al. 2003;
Kuna et al. 2007) in large clinical trials. The application
of additional or new small molecule therapies, in the
form of phosphodiesterase (PDE) inhibitors with and
without steroid/ b2 agonist combinations, is of much
interest to the pharmaceutical industry and academia to
identify improved future therapies that will prevent
asthma and COPD exacerbations.
PDEs are enzymes that catalyze the cleavage of a
phosphodiester bond, often in the context of a cyclic
nucleotide. PDEs comprise a group of enzymes that
degrade the phosphodiester bond in the second messen-
ger molecules cAMP and cGMP, thus regulating a range
of cellular processes including intracellular signal trans-
duction pathways. There are 11 families in mammals
(PDE1-11), and Type 4 (PDE4) is cAMP-specific PDEs
encoded by four genes (PDE4A, PDE4B, PDE4C, and
PDE4D) sharing a highly conserved catalytic domain.
PDE4 is the major cAMP metabolizing enzyme found in
immune cells and is also present in lung structural cells,
including airway smooth muscle, epithelial cells,
endothelial cells, and fibroblasts (Billington et al. 2008;
Fuhrmann et al. 1999; Seybold et al. 1998). PDE4 inhibi-
tors have proven potential as anti-inflammatory drugs in
chronic airway diseases. By increasing intracellular cAMP
levels, PDE4 inhibitors elicit a broad spectrum of anti-
inflammatory effects, including the suppression of the
release of mucins (Mata et al. 2005), inflammatory
cytokines, and other mediators (Buenestado et al. 2011;
Burgess et al. 2006; Ouagued et al. 2005), and also inhi-
bit the actions of reactive oxygen species which are
proinflammatory in nature (Brown et al. 2007; de Visser
et al. 2011; Ortiz et al. 2012).
PDE4 inhibitors have been extensively trialed in asthma
and COPD (Bousquet et al. 2006; Compton et al. 2001;
Gamble et al. 2003; Louw et al. 2007; van Schalkwyk
et al. 2005). In stable disease, roflumilast and cilomilast
have shown significant improvements in lung function
and symptom score and may reduce rescue medication
use (Bousquet et al. 2006; Compton et al. 2001; Louw
et al. 2007). PDE4 inhibitors have also reduced COPD
exacerbation rates (Calverley et al. 2007b; Rennard et al.
2011) although few studies have specifically investigated
the effects of PDE4 inhibitors on virus-induced inflam-
mation (Ikemura et al. 2000; Van Ly et al. 2013). Roli-
pram was previously shown to reduce RSV-induced
eosinophilia and airway hyperresponsiveness in a mouse
model (Ikemura et al. 2000) and piclamilast failed to sup-
press RV-induced inflammatory mediators from airway
smooth muscle cells and primary human bronchial
epithelial cells, but suppressed inflammatory responses
following stimulation with the toll-like receptor (TLR)-3
agonist polyIC (Van Ly et al. 2013). Clearly, little is
known about the potential of PDE4 inhibitors to reduce
virus-induced inflammation, by what mechanism(s) they
act upon, and therefore, how this relates to the observed
clinical benefits on exacerbation rates seen in clinical
trials.
The clinical dosage and efficacy of the only oral PDE4
inhibitor currently approved in COPD (roflumilast) is
limited by target-related side effects, such as nausea, diar-
rhea, and headaches. Inhibitors specifically designed for
inhaled treatment may combine potent anti-inflammatory
activity with improved tolerability. One example is
CHF6001, a novel highly potent and selective PDE4 inhi-
bitor with robust anti-inflammatory activity and suitable
for topical pulmonary administration (Armani et al.
2014). In this study, we compared anti-inflammatory
effects of CHF6001 with that of roflumilast, using in vitro
models of virus-induced cytokine mRNA induction and
protein release. In certain experiments, CHF6001 was
used in combination with the inhaled steroid fluticasone
propionate (FP). We found that CHF6001 had suppres-
sive effects on RV-induced interferon (IFN)-b, IFN-k1
(IL-29), IFN-k2/3 (IL-28A/B), IL-8, IP-10, and RANTES
when used as a pretreatment, while roflumilast had no
suppressive effects when used as a pretreatment only. In
comparisons between CHF6001 as a pretreatment and
roflumilast as a pretreatment and posttreatment,
CHF6001 had a higher potency but equal efficacy. In
combination with low-dose FP, low-dose CHF6001 had
additive effects with potential for both steroid and PDE4
inhibitor sparing activity.
Materials and Methods
Reagents and compounds
CHF6001, roflumilast, and FP were obtained from Chiesi
Farmaceutici as solid chemicals and were made up in
Dimethyl sulfoxide (DMSO) at 0.1 mol/L solutions,
aliquoted, and stored at 20°C. A fresh aliquot was used
for each experiment.
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Cells and viruses
BEAS-2B cells (European Collection of Cell Cultures) were
cultured in Roswell Park Memorial Institute medium
(RPMI) with 10% FCS (Invitrogen, Paisley, UK). Minor
group RV1B (genotype RV-A) was grown in HeLa cells.
The RV1B stock was thoroughly assessed prior to use, was
mycoplasma free, and induced cytokines in a dose respon-
sive and replication-dependent manner. The RV1B stock
was diluted ¼ in RPMI medium, an approximate multiplic-
ity of infection (MOI) of 1 for all experiments.
Pretreatment and posttreatment of cells
and infection of BEAS-2B cells
BEAS-2B cells seeded into 12-well plates (Nunc) and left
overnight. The next day, cells were placed into RPMI med-
ium containing 2% FCS overnight. BEAS-2B cells were
then treated with CHF6001, roflumilast, or vehicle with
and without FP. Typically, both CHF6001 and roflumilast
were used in 7-point dose–response curves (1000–
0.001 nmol/L) diluted in RPMI medium as a 1.5-h
pretreatment prior to infection or as a pretreatment and
posttreatment. The amount of vehicle (DMSO) was kept
constant (1/100,000 dilution) for each dose of compound
or control used. In certain experiments, FP was also used
and diluted in RPMI medium to 1 or 10 nmol/L. Follow-
ing pretreatment, BEAS-2B cells were then infected with
RV1B or treated with medium for 1 h with shaking at
room temperature. Virus was washed off cells by 3X washes
in RPMI+2% FCS, and fresh medium was replaced and
lysates or supernatants harvested at 24 h post infection.
RNA extraction, cDNA synthesis, and
quantitative PCR
Total RNA was extracted from BEAS-2B cells (RNeasy
kit, Qiagen, Manchester, UK), and approximately 2 lg
was used for cDNA synthesis (Omniscript RT kit, Qia-
gen). Quantitative PCR was carried out using specific pri-
mers and probes for each gene (Bartlett et al. 2012;
Gielen et al. 2010). Reactions were analyzed using an ABI
7500 TaqMan, (ABI Foster City, CA). Each gene was nor-
malized to 18S rRNA and expressed as copies per lL
cDNA reaction using a standard curve based on amplifi-
cation with plasmid DNA.
ELISA analysis of cytokine production
Enzyme-linked immunosorbent assays (ELISA) for IL-8/
CXCL8, IP-10/CXCL10, RANTES/RANTES, and IFN-k1
(IL-29) were from R&D Systems (Abingdon, UK). The
ELISA kit (R&D Systems) for IFN-k1 measures both IL-
29 and IL-28 together and cannot discriminate between
the two. All ELISAs were used according to the manufac-
turer’s recommended protocol.
Statistical analysis
All in vitro experiments were performed 4–6 times; all data
expressed as mean  SEM. EC50s rather than IC50s were
calculated for all dose–response curves, and this curve con-
siders a plateau for efficacy, as full suppression or suppres-
sion beyond 50% of the induced cytokines was not
achieved. The equation used describes a sigmoidal dose–re-
sponse calculating Y = Bottom + (TopBottom)/
(1 + 10^((LogEC50X))), where X is the logarithm of con-
centration, Y is the response, Y starts at bottom and goes to
top with a sigmoid shape. For multiple comparisons, data
were analyzed by one-way analysis of variance and Bonfer-
roni’s multiple comparison test. For differences between
two groups, a Student’s t-test was employed. All statistics
were performed using Graph Pad Prism 4 software (San
Diego, CA USA), with P < 0.05 taken as significant.
Results
Human RV1B infection induced IL-8/CXCL8,
IL-29, IP-10/CXCL10, and RANTES/RANTES
mRNA and protein in bronchial epithelial
cell lines
The raw data of cytokine mRNA and protein induction
are shown in Table 1. At 24 h, BEAS-2B cells demon-
strated a robust, significant induction of each cytokine
mRNA and protein after infection with RV1B compared
with medium-treated cultures. These data show similar
robust levels of induction to previous published data with
this cell type following RV infection in vitro (Edwards
et al. 2006; Wang et al. 2009), and that the data in this
article presented as percentage of RV1B-infected controls
are based on statistically significant inductions of each
cytokine measured.
CHF6001 reduced RV1B induced IL-8, IL-29,
IP-10, and RANTES mRNA and protein in a
concentration-dependent manner
We first assessed CHF6001 as a pretreatment and found
dose-dependent suppressive effects on RV1B-induced
cytokine mRNA and protein. Figure 1 demonstrates
7-point dose–response curves for CHF6001 and shows
that CHF6001 as a pretreatment did exhibit suppressive
activity against each cytokine mRNA measured.
CHF6001 robustly suppressed IFN-b, IL-29, IL-28,
RANTES, and IP-10 mRNA expression and showed less
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suppressive effects on IL-8 mRNA (Fig. 1). These trends
were also reflected in the respective EC50 calculations
(Table 2), which were between 0.31 and 0.17 nmol/L. The
effects on protein release are shown in Figure 2. We
could not detect any IFN-b protein in these supernatants
and so could not assess the effects on protein release of
this cytokine (data not shown). CHF6001 had similar
effects on IL-29, IL-8, IP-10, and RANTES protein when
compared with the mRNA data, with similar subnanomo-
lar EC50s (Table 3). The effects of CHF6001 and roflumi-
last (at doses giving maximal suppression) on raw mRNA
and protein levels are additionally shown in Tables S1–S2.
Roflumilast reduced RV1B-induced cytokine
and IFN mRNA and protein in a
concentration-dependent manner
We initially used roflumilast as a pretreatment only but
found no effect on any RV1B-induced cytokine measured
(data not shown). We, therefore, opted to use roflumilast
as a pretreatment and posttreatment. Figure 3 demon-
strates 7-point dose–response curves for roflumilast, and
they indicate that roflumilast as a pretreatment and
posttreatment did exhibit suppressive activity against
each cytokine mRNA measured. Roflumilast robustly
Table 1. RV1B infection of BEAS-2B cells significantly induced the
mRNA and protein of proinflammatory cytokines and IFNs.
Gene/protein
Medium
(mean  SEM)
RV1B
(mean  SEM) P-value
mRNA quantification (copy number per lL cDNA)
IFN-b 2.9  1.0 9 103 4.7  1.1 9 105 <0.001
IL-29 0.01  0.0 9 103 1.0  0.51 9 105 <0.001
IL-28 0  0 9 103 3.2  1.2 9 105 <0.001
IL-8 4.9  3.0 9 105 6.5  0.89 9 106 <0.001
IP-10 1.3  0.81 9 103 1.1  0.31 9 107 <0.001
RANTES 1.3  0.39 9 103 1.0  0.4.1 9 107 <0.001
Protein Quantification (pg/mL)
IL-29 0.97  0.71 9 101 0.35  0.01 9 103 <0.001
IL-8 6.2  0.62 9 101 0.62  0.12 9 103 <0.01
IP-10 1.5  0.88 9 101 1.2  0.26 9 103 <0.01
RANTES 0.18  0.07 9 101 0.60  0.2 9 103 <0.05
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Figure 1. Pretreatment with CHF6001 suppressed RV-induced proinflammatory cytokines and IFN mRNA in a dose-dependent manner. BEAS-2B
cells were pretreated with CHF6001 at various doses for 1.5 h and then infected with RV1B (MOI = 1). At 24 h post infection, total RNA was
harvested, cDNA synthesized, and cytokine mRNA abundance determined by quantitative PCR. CHF6001 showed a dose-dependent suppression
of IFN-b mRNA (A), IL-29 mRNA (B), IL-28 mRNA (C), IL-8 mRNA (D), IP-10 mRNA (E), and RANTES mRNA (F). EC50 and r
2 values are shown for
each graph n = 7 experiments.
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suppressed IL-29, IL-28, RANTES, and IP-10 mRNA
expression and showed less suppressive effects on IFN-b
and CXCL8 mRNA (Fig. 3). These trends were also
reflected in the respective EC50 calculations (Table 2).
We also assessed the effects of roflumilast pretreatment
and posttreatment on cytokine release (Fig. 4). In a simi-
lar manner to the mRNAs, roflumilast showed dose-
dependent suppressive effects on each cytokine protein
measured. The EC50 values are presented in Table 3.
Comparison between CHF6001 and
roflumilast
We next compared relative potencies and efficacies of
CHF6001 pretreatment with roflumilast used as a pre-
treatment and posttreatment. These comparisons are
summarized in Tables 2 and 3 for mRNA and protein
release, respectively. Table 2 compares both the EC50s
and the maximal suppression for mRNA of each
Table 2. Comparison of CHF6001 and roflumilast in suppression of RV1B-induced cytokine mRNA.
Gene
CHF6001 Roflumilast CHF6001 versus Roflumilast
EC50 (nmol/L) Maximum suppression (%)
1 EC50 (nmol/L) Maximum suppression (%)
1 EC50 fold difference P-value
2
IFN-b 0.17 67  9.2 8.7 59  11 51 0.55
IL-28 0.29 58  8.0 1.1 69  8.5 3.9 0.37
IL-29 0.31 64  5.8 1.3 75  9.0 4.3 0.35
IL-8 0.26 46  8.3 No fit 60  8.6 – 0.25
IP-10 0.29 80  4.4 4.6 78  4.5 16 0.82
RANTES 0.24 61  6.9 0.7 65  8.0 3.0 0.75
1At any dose of compound tested.
2Comparison of maximum suppression at any dose CHF6001 versus roflumilast by unpaired t-test.
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Figure 2. Pretreatment with CHF6001 suppressed RV-induced proinflammatory cytokines and IFN protein in a dose-dependent manner. BEAS-2B
cells were pretreated with CHF6001 at various doses for 1.5 h and then infected with RV1B (MOI = 1). At 24 h post infection, cell supernatants
were harvested, and cytokine release determined by ELISA. CHF6001 showed a dose-dependent suppression of IL-29 (A), IL-8 (B), IP-10 (C), and
RANTES (D). EC50 and r
2 values are shown for each graph n = 7 experiments.
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cytokine, found at any dose. We found that the maximal
suppression between CHF6001 and roflumilast was not
significantly different, indicating an equal efficacy. We
did find differences between the EC50 values, with
CHF6001 having lower EC50s, on average 13-fold lower
but with a wide range approximately, 51.3 fold
(Table 2). IFN-b was the most differentially affected
mRNA by the two drugs (51.4-fold difference). We also
compared protein release and found again similar, non-
significant maximal levels of suppression but differences
in EC50. The average difference in EC50 was approxi-
mately 16-fold, with a range of 3- to 48-fold. Interest-
ingly, IL-8 was the cytokine most differentially
suppressed between CHF6001 and roflumilast (47.5-fold
difference), with IL-29 being the least (3.54-fold
difference).
Table 3. Comparison of CHF6001 and roflumilast in suppression of RV1B-induced cytokine release.
Protein
CHF6001 Roflumilast CHF6001 versus Roflumilast
EC50 (nmol/L) Maximum suppression (%)
1 EC50 (nmol/L) Maximum suppression (%)
1 EC50 fold difference P-value
2
IL-29 0.41 76  3.0 1.5 85  5.2 3.6 0.15
IL-8 0.08 43  6.4 3.8 40  7.5 48 0.45
IP-10 0.38 64  3.2 2.6 73  4.0 6.8 0.37
RANTES 0.26 59  3.5 1.5 65  6.0 5.8 0.16
1At any dose of compound tested.
2Comparison of maximum suppression at any dose CHF6001 versus roflumilast by unpaired t-test.
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Figure 3. Pretreatment and posttreatment with roflumilast suppressed proinflammatory cytokines and IFN mRNA in a dose-dependent manner.
BEAS-2B cells were pretreated with roflumilast at various doses for 1.5 h and then infected with RV1B (MOI = 1). Roflumilast was added back
into the culture medium and cells incubated. At 24 h post infection, total RNA was harvested, cDNA synthesized, and cytokine mRNA abundance
determined by quantitative PCR. Roflumilast showed a dose-dependent suppression of IFN-b mRNA (A), IL-29 mRNA (B), IL-28 mRNA (C), IL-8
mRNA (D), IP-10 mRNA (E), and RANTES mRNA (F). EC50 and r
2 values are shown for each graph n = 6 experiments.
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CHF6001 had no effect on RV1B replication
As both CHF6001 reduced RV1B-induced IFN-b, IL-29,
and IL-28 mRNA and IL-29 protein, we sought to exam-
ine the effects on RV replication. At 24 h post infection,
we saw no effect on RV replication using both a titration
assay measuring virus release and quantitative PCR mea-
suring virus RNA (Table S3).
Additive effects of combined FP and
CHF6001 on RV1B-induced IL-8, IL-29, IP-10,
and RANTES/RANTES protein
We next assessed if the suppressive effects of CHF6001
could be observed in the presence of steroid and if steroid
and CHF6001 had additive or synergistic suppressive
effects. We first chose FP at 109 mol/L (1 nmol/L) as
this concentration is approximately the EC50 for these
cytokines in bronchial epithelial models (Edwards et al.
2007, 2006), and FP has been found at approximately this
concentration in lung tissue following inhalation
(Esmailpour et al. 1997). For all cytokines measured, FP
at 109 mol/L and CHF6001 at 106 mol/L used alone
significantly reduced cytokine levels compared with
RV1B-infected cells without pretreatment (Fig. 5A–D).
Figure 5A also demonstrates that CHF6001 at 106–109
when combined with FP at 109 mol/L (1 nmol/L) had
significantly reduced suppression of IL-29 compared with
FP alone but not with CHF6001 alone at 106 mol/L.
CHF6001 at 106–109 with FP showed significantly
reduced suppression of IL-8 compared with CHF6001
106 mol/L but not with FP alone (Fig. 5B). Data for
IP-10 and RANTES were quite similar, with CHF6001
at 106–108 mol/L with FP had significantly reduced
suppression compared with FP and CHF6001 alone at
106 mol/L (Fig. 5C); but for RANTES, CHF6001 at
106–108 mol/L with FP had significantly reduced sup-
pression compared with FP alone and reduced suppression
compared with CHF6001 106 mol/L for concentrations
106–109 mol/L (Fig. 5D).
We also assessed potential additive/synergistic effects
using FP at a lower dose, 1010 mol/L: (0.1 nmol/L). For
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Figure 4. Pretreatment and posttreatment with roflumilast suppressed proinflammatory cytokines and IFN protein in a dose-dependent manner.
BEAS-2B cells were pretreated with CHF6001 at various doses for 1.5 h and then infected with RV1B (MOI = 1). Roflumilast was added back into
the culture medium and cells incubated. At 24 h post infection, cell supernatants were harvested, and cytokine release determined by ELISA.
Roflumilast showed a dose-dependent suppression of IL-29 (A), IL-8 (B), IP-10 (C), and RANTES (D) cytokine release. EC50 and r
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all cytokines tested, FP showed no significant reduction,
while CHF6001 failed to reduce IL-8 but significantly
reduced the other three cytokines tested (Fig. 6A–D).
CHF6001 at 106–108 when cultured with FP signifi-
cantly reduced suppression of IL-29 compared with FP
alone but not with CHF6001 alone at 106 mol/L.
(Fig. 6A). CHF6001 at 106–109 with FP showed signifi-
cantly reduced suppression of IL-8 compared with
CHF6001 106 mol/L but not with FP alone (Fig. 6B).
Data for IP-10 and RANTES again were quite similar,
with CHF6001 at 106–109 mol/L with FP significantly
reducing suppression compared with FP but not
CHF6001 alone at 106 mol/L (Fig. 6C). For RANTES,
CHF6001 at 106–108 mol/L with FP at 1010 mol/L
had significantly reduced suppression compared with FP
alone but not when compared with CHF6001 106 mol/L
for concentrations at any concentration tested (Fig. 6D).
Steroid and PDE4 inhibitor sparing effects
of CHF6001 and FP when used in
combination
We also compared the effects of combined, low-dose
CHF6001 109 mol/L and FP 1010 mol/L with that of
higher dose CHF6001 (106 mol/L) and FP (109 mol/L,
Table 4). For IL-29, we found that the low-dose combina-
tion gave similar levels of suppression when compared
with FP at 109 mol/L and CHF6001 at 106 mol/L. The
levels of suppression for the combination when compared
with CHF6001 106 mol/L were not as impressive but
were not statistically different. For all other cytokines
tested, the data were similar in that the combination gave
similar levels to either higher dose FP at 109 mol/L or
high-dose CHF6001 at 106 mol/L. Of note, the levels of
suppression for the combination for IP-10 were better,
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Figure 5. Combined effects of CHF6001 and FP 109 mol/L on RV induced IFN and inflammatory cytokine protein release. BEAS-2B cells were
pretreated with CHF6001 at various doses (CHF6001-6, 7, 8, 9) and/or FP at 109 mol/L (FP-9), for 1.5 h and then infected with RV1B
(MOI = 1). At 24 h post infection, cell supernatants were harvested, and cytokine release determined by ELISA. Combined CHF6001 and FP at all
doses showed enhanced suppression of IL-29 that was significantly different from RV1B infection alone, and FP but not CHF6001 at 106 mol/L
(A). Combined CHF6001 and FP at all doses showed enhanced suppression of IL-8 that was significantly different from RV1B infection alone, FP,
and also CHF6001 at 106 M alone (B). Combined CHF6001 and FP at all doses showed enhanced suppression of IP-10 that was significantly
different from RV1B infection alone, and FP and for CHF6001 with FP at doses 106–108 M but not at 109 M. Enhanced suppression versus FP
was also seen for CHF6001 with FP at 106–108 M but not for 109 M. (C) Combined CHF6001 and FP at all doses showed enhanced
suppression of RANTES that was significantly different from RV1B infection alone, and FP, and for CHF6001 with FP at doses 106–108 M but not
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but not statistically different to either high-dose treatment
used alone.
Discussion and Conclusions
In this study, we compared two PDE4 inhibitors, roflumi-
last and CHF6001, for suppressive activity of virus-induced
cytokines and IFNs. While showing potential as therapies
in stable asthma and COPD and also exacerbations of
COPD (Calverley et al. 2007b; Rennard et al. 2011), few
studies have investigated the effects of PDE4 inhibitors in
the control of virus-induced inflammation (Ikemura et al.
2000; Van Ly et al. 2013). CHF6001 is a new inhaled highly
specific PDE4 inhibitor that may have improved activity
and potency (Moretto et al., 2015; Villetti et al., 2015).
In our present study, we compared the relative efficacy
and potency of CHF6001 and roflumilast on virus-induced
cytokines. Unfortunately, we did not plan experiments to
observe the effects of either roflumilast or CHF6001 on
basal cytokine expression in the absence of infection.
Considering the doses used, we would not expect either of
these agents to spontaneously induce cytokine expression.
Consistently for all cytokines tested, CHF6001 as a pre-
treatment had a similar level of efficacy to roflumilast,
when used as a pretreatment and posttreatment. The fact
that, unlike for CHF6001, pretreatment only with roflumi-
last gave no suppression for any cytokine measured sug-
gests that CHF6001 is more tightly engaged to the target
than roflumilast, thus resistant to the washing step that
followed virus infection. This phenomena may be
explained by the previously described very slow dissocia-
tion kinetic (t1/2 > 20 h) of CHF6001 (compound 32a)
(Armani et al. 2014). When we compared a pretreatment
of CHF6001 with pretreatment and posttreatment of
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Figure 6. Combined effects of CHF6001 and FP 1010 M on RV-induced IFN and inflammatory cytokine protein release. BEAS-2B cells were
pretreated with CHF6001 at various doses (CHF6001 6, 7, 8, 9) and or FP at 1010 M (FP-10), for 1.5 h and then infected with RV1B
(MOI=1). At 24 h post infection, cell supernatants were harvested, and cytokine release determined by ELISA. Combined CHF6001 and FP at 106-
108 M showed enhanced suppression of IL-29 that was significantly different from RV1B infection alone, and FP but not CHF6001 at 106 M (A).
Combined CHF6001 and FP at all doses showed enhanced suppression of IL-8 that was significantly different from RV1B infection alone, also
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roflumilast, levels of suppression where not significantly
different however, and no treatment reduced cytokine
mRNA and protein levels to baseline. In the best case
scenario, the maximum suppression was approximately
80–85% for both compounds; however, not every cytokine
exhibited this level of suppression. We did not investigate
the effects of CHF6001 as a pretreatment and posttreat-
ment, and it is possible that this level of suppression could
be improved further if this strategy was undertaken.
CHF6001 produced lower EC50 values than roflumilast, on
average approximately 13- to 16-fold lower; definitive evi-
dence that CHF6001 is more potent than roflumilast.
CHF6001 (compound 32a) was selected from a screen
partly on its ability to make extended interactions with all
three regions of the PDE4B catalytic binding pocket,
resulting in potentially improved inhibitory potency
(Armani et al. 2014). Furthermore, CHF6001 potently
(subnanomolar IC50 values) inhibited TNF-a release from
human peripheral blood mononuclear cells and the release
of IFN-c from CD4(+) T cells (Moretto et al. 2015). In all
these functional assays, CHF6001 was more potent than
previously described PDE4 inhibitors, including roflumi-
last (Moretto et al. 2015). In summary, the improved
potency and implied better efficacy versus roflumilast seen
in our studies is in line with other studies.
We also assessed CHF6001 in combination with the
steroid, FP. Previous studies have shown that other cAMP
elevating agents such as b2 agonists can synergize with
steroids, further reducing virus-induced inflammation
(Edwards et al. 2006; Skevaki et al. 2009). We found evi-
dence that low-dose CHF6001 (108 mol/L), when used
together with FP (109 mol/L), gave a greater suppressive
effect than FP 109 mol/L or high-dose CHF6001
106 mol/L. Additionally, high-dose CHF6001 (106
mol/L), when used together with low dose of FP
(1010 mol/L), gave a comparable suppressive effect to
that of FP 109 mol/L. This possibly suggests a steroid
sparing effect, and that as a combination, it might be pos-
sible that doses of both agents could be reduced (up to
10-fold) for the same therapeutic effect. The effect of both
drugs was additive rather than synergistic. Complete
comparisons between how FP affects the CHF6001 dose–
response curve or how CHF6001 might alter the FP dose–
response curve were not made, however, and would be
needed to ascertain a definitive understanding of the
pharmacology of both drugs. However, the data do point
to a potential beneficial suppressive effect of CHF6001
when used in conjunction with steroids. How both agents
work together are worthy of further study. Other studies
have reported additive effects of cAMP elevating agents
on both expression and activation of the glucocorticoid
receptor (GR), including both b2 agonists and PDE4 inhi-
bitors (Ortiz et al. 2012; Roth et al. 2002). Investigating
either expression or activation of the GR was, however,
beyond the scope of our experiments. It is possible
though that CHF6001 could be acting via the GR, such as
increasing its activation, or by acting on the same
pathways thus having an additive suppressive effect. In
support of this, Moodley et al. (2013) have shown that
combined roflumilast and FP treatment enhanced GRE-
dependent reporter activity and several GRE responsive
anti-inflammatory genes. Further studies are required to
investigate the potential mechanism responsible for ster-
oid sparing effects of CHF6001.
Previous studies have explored how RV induces IFNs
and proinflammatory cytokines (Bartlett et al. 2012; Slater
et al. 2010; Wang et al. 2011, 2009; Zhu et al. 1997,
1996). Pattern recognition receptors (PRRs), such as
TLR-3 in the endosome, and the RIG-like helicases
(RLHs) retinoic acid-inducible gene-I and melanoma-dif-
ferentiated gene-5 in the cytoplasm sense viral RNA and
elicit a signaling pathway involving activation of the tran-
scription factors IRF3 and NF-jB p65/p50 that lead to
IFN and proinflammatory cytokine transcription, respec-
tively (Bartlett et al. 2012; Slater et al. 2010; Wang et al.
2011, 2009). While there is some controversy over
whether or not NF-jB p65 is required for RV-induced
IFN transcription (Bartlett et al. 2012), it is possible that
CHF6001 and roflumilast are suppressing both IRF3- and
NF-jB-mediated gene transcription, as we observed
Table 4. Steroid and PDE4 inhibitor sparing effects of combined low-dose FP + CHF6001 in suppression of RV1B-induced cytokine release.
Protein
FP at 109 mol/L CHF6001 at 106 mol/L FP 1010 + 109 mol/L CHF6001
FP + CHF6001 P-value
Suppression (%) Suppression (%) Suppression (%) Versus FP1 Versus CHF60012
IL-29 63  3.5 78  3.0 65  6.7 0.84 0.07
IL-8 63  5.4 27  7.2 50  12 0.28 0.14
IP-10 55  8.3 64  3.5 79  12 0.14 0.12
RANTES 63  3.6 58  3.2 50  13 0.25 0.40
1Comparison of suppression of high-dose FP 109 mol/L versus combined low-dose FP 1010 mol/L and CHF6001 109 mol/L by unpaired t-test.
2Comparison of suppression of high-dose CHF6001 109 mol/L versus combined low-dose FP 1010 mol/L and CHF6001 109 mol/L by unpaired
t-test.
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impressive suppression of proinflammatory cytokines and
IFNs using either treatment. Studies in other systems have
shown that PDE4 inhibitors can inhibit NF-jB p65 acti-
vation and NF-jB-driven inflammatory mediator release
(Herve et al. 2008; Kwak et al. 2005). Other studies sug-
gest that PDE4 inhibition may affect signaling intermedi-
ates upstream of NF-jB, such as the mitogen-activated
protein kinases (Kwak et al. 2005), and interfere with
reactive oxygen generation (Cheng et al. 2005). The
effects of PDE4 inhibitors on IRF3 signaling have not yet
been performed, although it is possible that activation of
this transcription factor is also targeted by PDE4 inhibi-
tors. More studies are required to understand how
CHF6001 and roflumilast suppress virus-induced cytoki-
nes and IFNs; in our experiments, it would also be inter-
esting to investigate if both TLR3 and RLH signaling are
affected, as previous studies suggest that TLR3 signaling
may be suppressed specifically (Van Ly et al. 2013). Our
studies were limited to NF-jB induced cytokines and
IFNs. It would be of interest to extend these studies to
other epithelial-derived cytokines, notably the pro-Th2
factors IL-33 and IL-25.
We found that both CHF6001 and roflumilast had
potent suppressive effects on RV-induced IFNs. Type I
IFN-b and type III IFN-ks are potent antiviral cytokines
involved in upregulating the intracellular antiviral
response as well as inducing other cytokines and
chemokines that activate various aspects of the innate
and adaptive immune system (Schneider et al. 2014). It
could be argued that suppressing beneficial antiviral
immunity in the context of asthma and COPD exacerba-
tions would be an unwanted outcome of a new therapy.
In fact, impaired antiviral immunity has been reported
in both asthmatic (Contoli et al. 2006; Edwards et al.
2012b; Uller et al. 2010) and COPD tissues (Mallia et al.
2010), and IFN-b has been recently trialed in a Phase I/
II study for efficacy on naturally occurring asthma
exacerbations (Djukanovic et al. 2014). Nevertheless,
suppression of the IFN pathways seen in our experi-
ments could simply be a necessary by-product for a
potent anti-inflammatory response to the viral infection
elicited by PDE4 inhibition. The clinical ramifications of
suppressing IFN are currently unknown and require fur-
ther study. Indeed, we also found that FP suppressed
RV-induced IFNs, alone and in combination with
CHF6001, yet steroids have been the traditional mainstay
of asthma and COPD treatment, and in some studies
have a beneficial effect in controlling exacerbation rate
or severity (Calverley et al. 2007a; Pauwels et al. 2003).
In addition, the use of roflumilast was associated with
reduced COPD exacerbations, which might be triggered
by viral infections, with the greatest benefits observed in
patients with severe COPD who had chronic bronchitis
and a history of frequent exacerbations (Lipari et al.
2013). In addition, no increase in the incidence of either
influenza-like symptoms or upper respiratory tract
infections in COPD patients treated with roflumilast was
observed (Chong et al. 2013).
We also found that CHF6001 did not significantly alter
RV replication in our experiments, measured either as a
titration assays or qPCR for virus RNA. Considering the
suppressive effects of both treatments on IFNs, this result
is perhaps surprising. A possible explanation for these
results is the fact that we only measured virus release or
RNA levels at 24 h. Changes in virus induced IFN at
24 h are unlikely to alter virus replication at 24 h,
although we cannot exclude an effect on virus replication
at later time points (Edwards et al. 2012b). Roflumilast
was previously shown to suppress RSV infection at day
10 post infection using airway epithelial cells in air–liquid
interface cultures (Mata et al. 2013). While the exact
mechanism was not defined in this study, the authors
believed that inhibition of RSV attachment and entry
may at least, in part, explain these phenomena. Our own
results are clearly different, which may reflect virus- or
culture-specific effects as well a study design that was not
set up to examine the effects of PDE4 inhibitors on RV
replication.
In summary, have shown that a new PDE4 inhibitor
CHF6001 has anti-inflammatory activity using in vitro
models of virus infection, providing evidence that this
class of inhibitor may be effective in clinical studies of
asthma and COPD exacerbations. Comparisons with the
PDE4 inhibitor roflumilast, which is used in severe
COPD patients with frequent exacerbations, showed that
CHF6001 had greater potency and likely improved
efficacy as an anti-inflammatory. Importantly, future
experiments should be performed in preclinical animal
models to investigate how CHF6001 (topical) compares
to roflumilast which is given systemically. In conjunction
with steroids, CHF6001 gave enhanced anti-inflammatory
activity compared with equivalent doses of steroid or
CHF6001 when used alone, in an additive manner, and
was strongly suggestive of both a steroid and PDE4 inhi-
bitor sparing effect. Although the exact mechanisms of
how PDE4 inhibitors suppress virus-induced inflamma-
tion remain to be elucidated, the data support the use of
PDE4 inhibitors in exacerbations of chronic airways
diseases.
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